Shaanxi Meibang Pharmaceutical Group Co Ltd

Meibang Shares announced that its board of directors has approved a proposal to increase capital in its wholly-owned subsidiary Shaanxi Nuozheng Biotechnology Co., Ltd. by 80 million yuan, and to invest in establishing a wholly-owned Hong Kong subsidiary with registered capital of 500,000 Hong Kong dollars, with the company holding 100% equity.

Meibang Shares released its 2026 interim report on July 30, 2026. The company's total operating revenue was 555 million yuan, and net profit attributable to the parent was 51.0674 million yuan. Net cash flow from operating activities was negative 329 million yuan, a decrease of 115 million yuan compared to the same period last year. The company's latest asset-liability ratio was 35.80%, up 1.66 percentage points from the same period last year, gross margin was 37.24%, ROE was 4.29%, and diluted earnings per share was 0.38 yuan.